CAJ | 학술논문

目的：研究低剂量地西他滨是否可增强T细胞对宫颈癌细胞杀伤活性，并探讨其可能的作用机制。方法 CCK-8检测低剂量地西他滨对宫颈癌细胞增殖的影响，流式细胞仪检测低剂量地西他滨处理后宫颈癌细胞凋亡及周期的变化；CCK-8检测T细胞对低剂量地西他滨处理后宫颈癌细胞的杀伤作用，实时定量PCR法检测地西他滨处理后宫颈癌细胞癌/睾丸抗原(cancer testis antigen，CTA)及FasL的mRNA表达的变化。结果10 nmol/L地西他滨对宫颈癌细胞增殖、凋亡没有显著影响，100 nmol/L地西他滨一定程度上抑制细胞增殖。10 nmol/L地西他滨虽不直接抑制细胞增长，但使宫颈癌细胞对T细胞的杀伤效应更为敏感，以效靶比为10∶1时最显著。10 nmol/L地西他滨处理后宫颈癌细胞BORIS、NY-ESO-1、MAGE-A1/A3/A4等CTA及FasL的mRNA水平显著上调(P＜0.05)。结论低剂量地西他滨可抑制Hela及SiHa细胞的生长及存活，增强T细胞对Hela及SiHa细胞的杀伤能力，是一个潜在的免疫治疗辅助药物。
목적：연구저제량지서타빈시부가증강T세포대궁경암세포살상활성，병탐토기가능적작용궤제。방법 CCK-8검측저제량지서타빈대궁경암세포증식적영향，류식세포의검측저제량지서타빈처리후궁경암세포조망급주기적변화；CCK-8검측T세포대저제량지서타빈처리후궁경암세포적살상작용，실시정량PCR법검측지서타빈처리후궁경암세포암/고환항원(cancer testis antigen，CTA)급FasL적mRNA표체적변화。결과10 nmol/L지서타빈대궁경암세포증식、조망몰유현저영향，100 nmol/L지서타빈일정정도상억제세포증식。10 nmol/L지서타빈수불직접억제세포증장，단사궁경암세포대T세포적살상효응경위민감，이효파비위10∶1시최현저。10 nmol/L지서타빈처리후궁경암세포BORIS、NY-ESO-1、MAGE-A1/A3/A4등CTA급FasL적mRNA수평현저상조(P＜0.05)。결론저제량지서타빈가억제Hela급SiHa세포적생장급존활，증강T세포대Hela급SiHa세포적살상능력，시일개잠재적면역치료보조약물。
Objective To study the effect of T cell killing ability on low-dose decitabine (DAC) treated cervical cancer cells and explore its possible mechanism.Methods CCK-8 was used to test the proliferation of low-dose DAC treated cervical cancer cells. Flow cytometry assay was used to test the apoptosis and cell cycle of low-dose DAC treated cervical cancer cells. CCK-8 was also used to test T cell killing ability of low-dose DAC treated cervical cancer cells. Real-Time PCR was used to test the expression of BORIS, NYESO-1, MAGEA1, MAGEA3, MAGEA4 and FasL on low-dose DAC treated cervical cancer cells.Results 10 nmol/L of DAC showed no significant difference in the proliferation and apoptosis of cervical cancer cells, while 100 nmol/L of DAC inhibited the proliferation of cervical cancer cells. Though 10 nmol/L of DAC did not inhibit the proliferation of cervical cancer cells directly, it enhanced T cell killing ability to cervical cancer cells most significantly with the efficient targeting ratio of 10∶1. Also 10 nmol/L of DAC showed significant up-regulation in the mRNA expression of CTAs such as BORIS, NYESO-1, MAGEA1, MAGEA3 and MAGEA4, as well as FasL.Conclusion These results suggest that low-dose DAC may work as a potential biological immunotherapy drug to inhibit cell viability and enhance T cell killing ability in cervical cancer cells.